OBJECTIVES The advent of direct-acting antivirals (DAAs) has revealed high rates of sustained virological response at 12 weeks (SVR 12) in Hepatitis C (HCV) treatment. Since the introduction of DAAs, in our centre, 42% of patients treated for HCV are HIV co-infected. Our study aimed to identify the SVR 12 rates between this group and HCV mono-infected patients. METHODS Retrospective data analysis of HCV mono-infection and HIV-HCV co-infection patients between 1st July 2015 and 30th November 2018, who had a SVR at 12 weeks post treatment. Co-infected patients were only referred for HCV treatment if they had well controlled HIV. Patients treated with Pegylated Interferon and Ribavirin were excluded. RESULTS During this period, 724 patients were treated for HCV and had data on SVR 12. Of those, 303 (41.8%) were co-infected with HIV. The SVR 12 was achieved in 386 (91.6%) of the HIV negative patients and 288 (95%) of the HIV positive patients (χ²= 3.10 p = 0.078). Cirrhotic patients had poorer SVR 12 in both groups (90% in co-infection and 88.4% in HCV mono-infection). CONCLUSIONS Our results demonstrate a higher SVR 12 in co-infected patients compared to patients with HCV mono-infection. We hypothesise that adherence to HIV treatment could increase compliance and success of HCV treatment.

中文翻译：

---

HIV-HCV合并感染在12周时具有更高的持续病毒学应答率；大专以上学历。

目的直接作用抗病毒药物（DAA）的出现显示，丙型肝炎（HCV）治疗在12周（SVR 12）时具有很高的持续病毒学应答率。自从引入DAA以来，在我们中心，接受HCV治疗的患者中有42％被HIV感染。我们的研究旨在确定该人群与HCV单一感染患者之间的SVR 12比率。方法回顾性分析2015年7月1日至2018年11月30日之间在治疗后12周出现SVR的HCV单一感染和HIV-HCV合并感染患者。如果合并感染的患者的HIV控制良好，则仅接受HCV治疗。排除用聚乙二醇化干扰素和利巴韦林治疗的患者。结果在此期间，有724例接受HCV治疗并具有SVR 12数据的患者。其中303例（41.8％）感染了HIV。在386名（91.6％）的HIV阴性患者和288名（95％）的HIV阳性患者中实现了SVR 12（χ²= 3.10 p = 0.078）。肝硬化患者两组的SVR 12均较差（合并感染90％，HCV单一感染88.4％）。结论我们的结果表明，与HCV单一感染患者相比，合并感染患者的SVR 12更高。我们假设遵守HIV治疗可以提高HCV治疗的依从性和成功率。